Medicus Pharma

MDCX

Market cap $25.9M

Medicus Pharma (NASDAQ:MDCX) has marked the one-year anniversary of its Nasdaq listing on Thursday by ringing the Opening Bell at the Nasdaq MarketSite in New York's Times Square. CEO Dr Raza Bokhari said the company was honored with the opportunity, describing the milestone as a reflection of Medicus' progress since going public and its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio.

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Steve Darling from Proactive https://youtu.be/8EErx6aQEXs to announce that the company was honored with the opportunity to ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square, marking the one-year anniversary of Medicus' listing on the Nasdaq exchange.

Medicus Pharma (NASDAQ:MDCX) said on Thursday its subsidiary Antev Ltd has amended a licensing agreement with UK-based medical research organization LifeArc, reducing future royalties tied to the experimental drug Teverelix, a move the company said improves the asset's long-term commercial profile. Under the revised agreement, royalties payable on worldwide net sales of Teverelix have been cut to 2% from about 4%, with the royalty term clarified on a country-by-country basis, Medicus said.

Amendment reduces and simplifies royalty structure on Teverelix ® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix ® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its subsidiary, Antev Ltd.

Medicus Pharma (NASDAQ:MDCX) will ring the Nasdaq Opening Bell on January 22, marking its one-year Nasdaq anniversary. The biotech company focuses on advancing novel therapeutics, including SkinJect for basal cell carcinoma ($2 billion market) and Teverelix for advanced prostate cancer ($6 billion market).

PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company.

Medicus Pharma (NASDAQ:MDCX) announced that it will present new Phase 1 clinical data on its long-acting gonadotropin-releasing hormone (GnRH) antagonist Teverelix at the American Association of Clinical Endocrinology (AACE) Annual Meeting in April 2026. The company said its abstract, titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers,” has been accepted for e-Poster presentation at the meeting, which will be held April 22 to 24 in Las Vegas.

PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada.

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality

Medicus Pharma (NASDAQ:MDCX) earlier this week shared details of a planned collaboration with Reliant AI to improve clinical trial execution through artificial intelligence. The company's chief medical officer, Dr Faisal Mehmud, said the collaboration will focus initially on supporting the development of Teverelix, a compound that was acquired through Medicus's takeover of Antev during the summer.